Why the study?
Does perioperative FLOT improve overall survival compared to the CROSS regimen in patients with esophageal adenocarcinoma?
Does perioperative FLOT improve overall survival compared to the CROSS regimen in patients with esophageal adenocarcinoma?
This is the authors' abstract. We don't add key points for this paper.
The evidence presented by the Esophageal adenocarcinoma: peri-operative chemotherapy (ESOPEC) trial and the accompanying viewpoints highlight the importance of viewing these findings against the backdrop of heterogeneous clinical settings. While the trial demonstrated a clear survival advantage with perioperative Fluorouracil, Leucovarin, Oxaliplatin, Docetaxel (FLOT) in the intention-to-treat population, several factors influence how these results translate to routine practice. The central point of discussion has been the ‘underperformance’ of the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study (CROSS) arm compared with its original trial and with Neo-AEGIS. In ESOPEC, CROSS achieved a median overall survival of 37 months, lower than the ~43 months seen in the original CROSS trial and ~49 months in Neo-AEGIS.1 This discrepancy may reflect patient mix rather than regimen weakness. The ESOPEC cohort included ~80% node-positive patients (compared with ~60% in CROSS) and potentially longer or bulkier tumors (ESOPEC included T4 tumors while CROSS did not), both factors associated with worse outcomes.2 Furthermore, only a quarter of patients underwent Positron Emission Tomography Computed Tomography (PET-CT) staging, which could have led to understaging and inclusion of more advanced disease. The higher Pathological complete response (pCR) and survival rates seen in the CROSS trial were at least partially driven by the cohort with squamous histology. These nuances are critical when interpreting the survival gap.
Answers are grounded in this paper and cite their sources.
Perioperative FLOT demonstrates a survival advantage over the CROSS regimen in esophageal adenocarcinoma, though differences in patient baseline characteristics between trials complicate direct comparisons.
No takes yet. Share an insight, caveat, or question.
Jiwnani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: